Article Sidebar
Main Article Content
Abstract
Background: Breast cancer is 42.1 per 100,000 population with an average of 17 deaths per 100,000 population. Breast cancer management includes surgery, radiotherapy, chemotherapy and hormonal therapy. Neoadjuvant therapy has a several goals in breast cancer: reducing the volume of initially inoperable tumors, evaluating in vivo chemosensitivity and analyzing micrometastasis management. Cell proliferation is often measured through Ki67 resulting in independent prognostic markers and as predictive markers of responsiveness or resistance to chemotherapy or endocrine therapy. In breast cancer with high risk has a higher expression of Ki67, so it will have a worse prognosis. This study was conducted to find out the relationship of Ki67 pre chemotherapy neoadjuvant levels with prognosis in patients with stage IIIB breast cancer who performed mastectomy surgery at Moehammad Hoesin Palembang General Hospital.
Method: Cohort Retrospective research on 40 samples Breast cancer patients in the Medical Record Room and Anatomical Pathology Room of Dr. Moehammad Hoesin Palembang in July-September 2021.
Results: There were 14 out of 40 samples that had high Ki67 levels (>30%), chi square and fisher exact analysis showed Ki67 levels >30% were significantly associated with mortality (p<0.05, OR 13,8(2,7-70,2)). At cut off points Ki67 >20% is also significantly associated with mortality (p<0.05, OR 7,1 (0,8-63,1)) with a sensitivity value of 91,6% and specificity of 39,2%.
Conclusion: Ki67 >20% can be a worse prognosis in predicting death and overall survival.
Keywords
Article Details
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2.Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3.Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.